Clinical Trials Logo

Ocular Hypertension (OHT) clinical trials

View clinical trials related to Ocular Hypertension (OHT).

Filter by:
  • None
  • Page 1

NCT ID: NCT06249152 Recruiting - Glaucoma Clinical Trials

Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients

Start date: April 21, 2024
Phase: Phase 2
Study type: Interventional

Qlaris Phase 2 clinical study investigating the safety, tolerability, and ocular hypotensive efficacy of QLS-111 in combination with latanoprost in open-angle glaucoma (OAG) and/or ocular hypertension (OHT) patients.

NCT ID: NCT06016972 Recruiting - Clinical trials for Primary Open Angle Glaucoma (POAG)

Qlaris Phase 2 Study of QLS-111 in POAG and/or OHT Patients

Start date: March 15, 2024
Phase: Phase 2
Study type: Interventional

Qlaris' Phase 2 clinical trial investigating the safety, tolerability, and ocular hypotensive efficacy of QLS-111 in primary open-angle glaucoma (POAG) or ocular hypertension patients.

NCT ID: NCT02829996 Completed - Clinical trials for Ocular Hypertension (OHT)

Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With OHT or POAG

Start date: August 19, 2016
Phase: Phase 2
Study type: Interventional

Phase II, randomized, double-masked study to evaluate the efficacy and tolerability of topical ocular delivery of fixed-dosed combinations of trabodenoson and latanoprost in subjects with Ocular Hypertension or Primary Open-Angle Glaucoma. All subjects who meet the study's enrollment criteria following Screening will undergo washout of all prohibited medications (if washout is needed), including their routine glaucoma medications. During the Placebo Run-In Period, placebo is applied twice daily to both eyes in all subjects. During the Treatment Period, study drug is applied to both eyes for a total of 8 weeks. Each subject will be assigned 4 weeks of AM and 4 weeks of PM dosing in a masked manner. AM vs PM dosing is masked utilizing Placebo in addition to the active drug product. During the Treatment Period, study drug (Active and Placebo) eye drop applications will occur twice daily, in the morning and in the evening. The Treatment Period will be followed by an Observation Period of approximately 7 days wherein no study eye drops are instilled. The purpose of the study is to assess the overall benefit/risk profile of binocular topical application of different doses of trabodenoson (3.0% and 6.0%) when combined with latanoprost (0.005% or 0.0025%) one drop daily (QD) for 8 weeks.

NCT ID: NCT02565173 Completed - Clinical trials for Ocular Hypertension (OHT)

Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma

MATrX-1
Start date: September 2015
Phase: Phase 3
Study type: Interventional

Phase III trial involving topical application, in both eyes, of trabodenoson ophthalmic formulation 3.0% or 6.0% once per day or 4.5% twice per day, placebo twice per day, or timolol 0.5% twice per day for 12 weeks in adult subjects with Ocular Hypertension or Primary Open-Angle Glaucoma. All subjects who meet the study's enrollment criteria following Screening will undergo washout of all prohibited medications, including their routine glaucoma medications. During the Placebo Run-In Period, placebo is administered twice daily to both eyes in all subjects. During the Treatment Period, study drug is applied to both eyes for a total of 12 weeks followed by an Observation Period of approximately 7 days wherein no study eye drops are instilled. The purpose of the study is to assess the efficacy, tolerability, and safety of binocular topical application of trabodenoson ophthalmic formulation 3.0% or 6.0% QD or 4.5% BID for 12 weeks. Timolol is being included in the trial in order to have an active control to ensure the integrity of the trial from an efficacy perspective; the primary comparator for all statistical purposes is the placebo arm.

NCT ID: NCT02226094 Terminated - Clinical trials for Ocular Hypertension (OHT)

Safety and Efficacy of Deep Wave Trabeculoplasty (DWT) in Primary Open Angle Glaucoma and Ocular Hypertension

Start date: November 2013
Phase: Phase 1/Phase 2
Study type: Interventional

The primary purpose of this study is to investigate the safety and efficacy of bilateral DWT in subjects with POAG or OHT compared to active and sham controls. The secondary purpose of the study is to investigate the durability, repeatability, and does response of the same.

NCT ID: NCT01917383 Completed - Clinical trials for Ocular Hypertension (OHT)

A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma

Start date: August 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the intraocular pressure (IOP) lowering efficacy and the safety and tolerability profile of trabodenoson ophthalmic formulation compared to timolol maleate ophthalmic solution 0.5% in adults with ocular hypertension (OHT) or primary open-angle glaucoma (POAG) who are already receiving treatment with latanoprost ophthalmic solution 0.005% once every evening (QPM).

NCT ID: NCT01670266 Completed - Clinical trials for Ocular Hypertension (OHT)

Single and Multiple Dose Escalation and Two-sequence Crossover Study of ONO-9054 in Patients With Ocular Hypertension or Mild Open-angle Glaucoma

Start date: August 2012
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to evaluate the safety and tolerability of 3 planned doses of ONO-9054 in the eyes of adult male and female patients with ocular hypertension (OHT) or mild open angle-glaucoma (OAG). The secondary objectives are to evaluate Pharmacodynamics (PD) and to characterize the pharmacokinetic (PK) profile of ONO-9054 and its metabolite in plasma and to compare its tolerability following morning and evening dosing.

NCT ID: NCT01318252 Completed - Clinical trials for Ocular Hypertension (OHT)

AL-54478 Proof of Concept Study

Start date: June 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and efficacy of AL-54478 0.005% compared with Latanoprost 0.005% and AL-54478 Vehicle in patients with open-angle glaucoma or ocular hypertension.

NCT ID: NCT01180062 Terminated - Clinical trials for Primary Open Angle Glaucoma (POAG)

Safety Study of Latanoprost Slow Release Insert

Latanoprost SR
Start date: January 2011
Phase: Phase 1
Study type: Interventional

This study is a phase 1, open-label, dose-escalation, safety and tolerability study, which will be conducted at one study site. This study will include 3 cohorts. Each cohort will have approximately 5 subjects. Subjects will not be randomized into the study. The first cohort will receive low dose drug insert, second cohort will receive 2 low dose drug inserts thus achieving twice the drug levels compared to cohort I and third cohort will receive high dose drug insert.